2018 Head and Neck Cancers Symposium

Low Survival in Patients with Head and Neck Cancers Linked to Delays in Radiation Therapy After Surgery

Corbin Davis

May 2018, Vol 8, No 5 - 2018 Head and Neck Cancers Symposium

A shorter interval from surgery to the start of radiation therapy has been linked to improved survival in patients with head and neck cancers, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Results of a retrospective analysis showed that patients who received radiation within 42 days of surgery had a median overall survival (OS) of 10.5 years versus 8.2 years for those who received radiation 43 to 49 days after surgery. Moreover, when radiation was delayed by ≥50 days postsurgery, the median OS dropped to 6.5 years. The data also demonstrated improved OS for patients who received accelerated versus standard fractionated therapy, the investigators noted. [ Read More ]

Cabozantinib Active as First-Line Treatment of Differentiated Thyroid Cancer

Corbin Davis

May 2018, Vol 8, No 5 - 2018 Head and Neck Cancers Symposium

Results from a phase 2 clinical trial have shown that cabozantinib (Cometriq) is active in radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Cabozantinib induction therapy resulted in a 54% response rate and an 80% clinical benefit, meeting the study primary end point. The treatment was also well-tolerated, with mostly grade 1 and 2 adverse events. [ Read More ]